Welcome to our dedicated page for 10X Capital Venture Acquisition III news (Ticker: VCXB), a resource for investors and traders seeking the latest updates and insights on 10X Capital Venture Acquisition III stock.
10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) is a blank check company sponsored by 10X Capital, an alternative asset management firm. 10X Capital leverages advancements in data analytics and AI to generate signals, deliver insights, and drive returns across various asset classes. Committed to promoting Diversity, Equity & Inclusion, 10X Capital is among the most active venture capital firms globally, aligning Wall Street, Main Street, and Silicon Valley by bringing institutional capital and strategies to high-growth ventures and income opportunities in both private and public markets.
10X Capital Venture Acquisition Corp. III, also known as 10X III, focuses on identifying high-growth businesses domestically and abroad, bringing them to public markets through special purpose acquisition. Recently, 10X III made headlines by transferring the listing of its Class A ordinary shares, redeemable warrants, and units from the New York Stock Exchange to NYSE American LLC to benefit from more favorable listing thresholds.
In a noteworthy move, 10X III entered into a merger agreement with American Gene Technologies International Inc., aiming to create a publicly listed company named Addimmune. The parties intend to file relevant materials with the SEC, ensuring shareholders and potential investors have access to important information regarding the proposed business combination.
10X III recently faced compliance challenges with NYSE American's continued listing standards due to not timely filing its Quarterly Report for the quarter ending September 30, 2023. Nonetheless, the company promptly addressed the issue by filing the required report, thus regaining compliance. Additionally, 10X III was notified of not meeting the minimum shareholder requirement but plans to submit a compliance plan by February 28, 2024, to resolve this deficiency.
For more information and the latest updates, visit 10X III's official website or contact their investor relations at ir@10xcapital.com.
Sparks Energy, Inc. has announced a merger agreement with 10X Capital Venture Acquisition Corp. III (NYSE: VCXB). The transaction will create a publicly traded company under the ticker symbol 'SPKS'. Sparks specializes in power infrastructure recovery services, responding to outages caused by extreme weather across the U.S. With increasing demand due to climate change and investment in renewables, the merger positions Sparks for growth. The pro forma enterprise value of the combined entity is estimated at $475 million, aided by a $50 million equity facility, and is expected to close in 2023.
10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U) announced that starting March 4, 2022, investors can separately trade its Class A ordinary shares and warrants from its initial public offering units. The Class A ordinary shares will trade under the symbol VCXB and warrants under VCXBWS, while units that are not separated will continue trading as VCXB.U. It’s important to note that only whole warrants will be traded, and holders must contact Continental Stock Transfer & Trust Company for the separation process. The offering's registration statement was effective January 11, 2022.
10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U) has successfully completed its initial public offering of 30,000,000 units, raising gross proceeds of $300 million. The offering was upsized and included the exercise of an over-allotment option for an additional 3,900,000 units. Each unit comprises one Class A ordinary share and one-half of a redeemable warrant, with full warrants exercisable at $11.50 per share. The units and individual securities will trade under the symbols VCXB and VCXB.WS. Funds from the IPO are primarily allocated into a trust.
10X Capital Venture Acquisition Corp. III has announced the successful pricing of its initial public offering (IPO) of 26,100,000 units at $10.00 per unit. The units will trade on the NYSE under the ticker symbol VCXB.U starting January 12, 2022. Each unit consists of one Class A ordinary share and one-half of a redeemable warrant, with whole warrants exercisable to purchase one Class A share at $11.50.
As a blank-check company, its focus is on merging with high-growth technology businesses. Cantor Fitzgerald & Co. is managing the offering, with a 45-day option for underwriters to purchase additional units.
FAQ
What is the current stock price of 10X Capital Venture Acquisition III (VCXB)?
What is the market cap of 10X Capital Venture Acquisition III (VCXB)?
What is 10X Capital Venture Acquisition Corp. III?
What recent developments have occurred with 10X III?
What compliance challenges did 10X III face?
What is the significance of the merger with American Gene Technologies?
How does 10X Capital promote Diversity, Equity & Inclusion?
Where can I find more information on the merger and other updates?
How can investors contact 10X III for more information?
What are the trading symbols for 10X III on NYSE American?
What is the role of 10X Capital in 10X III?
What steps is 10X III taking to regain compliance with NYSE American's listing standards?
